Understanding the Epidemiology of Colorectal Cancer

A basic understanding of the epidemiology of colorectal cancer is important for general practitioners to consider when treating their patients. It is worth noting that 95% of colorectal cancer cases occur in individuals over the age of 50.

In terms of incorrect answer options, it is important to note that bowel cancer incidence rates have not increased by 6% over the last 10 years. Additionally, bowel cancer is not the second most common cause of cancer death in the UK overall, but rather in men alone it is second to prostate cancer and in women alone it is second to breast cancer.

Finally, while almost 42,000 people were diagnosed with bowel cancer in the UK in 2011, it is not accurate to say that half of patients diagnosed with colorectal cancer will survive their disease for 10 years or more. It is important for general practitioners to have accurate information about colorectal cancer in order to provide the best care for their patients.

Causes of Jaundice and their Characteristics

Jaundice can be caused by various conditions, each with their own unique characteristics. Cancer of the pancreas, particularly in the head, can cause painless jaundice. On the other hand, cancer in the body or tail of the pancreas can present with dull, unremitting central abdominal pain or back pain. Smoking is a known risk factor for pancreatic cancer.

Gilbert’s syndrome, a familial condition, can also cause jaundice. However, the jaundice in this case is pale yellow and the patient typically feels well. While Gilbert’s syndrome is not uncommon, it is important to consider other potential causes of jaundice, especially if the patient has significant weight loss. As a wise surgeon once said, People with IBS get Ca bowel too – never forget that.

Hepatitis A is more commonly seen in adolescents and young adults. Primary biliary cirrhosis, on the other hand, has its peak incidence in the fifth decade of life and often presents with generalized pruritus or asymptomatic hepatomegaly. Understanding the characteristics of different causes of jaundice can help in making an accurate diagnosis and providing appropriate treatment.

Helicobacter Infection and Treatment

Helicobacter infection is common in patients with duodenal and peptic ulceration. The recommended therapy includes acid suppression and eradication of Helicobacter. Triple therapy with a proton pump inhibitor (PPI) such as omeprazole, along with two antibiotics (amoxicillin/clarithromycin plus metronidazole), has been found to be highly effective.

It is important to note that patients who are allergic to penicillin require a different treatment regimen. The lowest cost treatment option should be chosen, taking into account previous exposure to clarithromycin or metronidazole. In cases where the patient is allergic to penicillin and has had previous exposure to clarithromycin, bismuth and tetracycline should be added to the treatment regimen.

The recommended PPI doses for Helicobacter pylori eradication therapy are esomeprazole 20 mg, lansoprazole 30 mg, omeprazole 20-40 mg, pantoprazole 40 mg, and rabeprazole 20 mg. It is important to follow these guidelines to ensure effective treatment of Helicobacter infection.

Scoring Systems for Liver Cirrhosis

Liver cirrhosis is a serious condition that can lead to liver failure and death. To assess the severity of the disease, doctors use scoring systems such as the Child-Pugh classification and the Model for End-Stage Liver Disease (MELD). The Child-Pugh classification takes into account five factors: bilirubin levels, albumin levels, prothrombin time, encephalopathy, and ascites. Each factor is assigned a score of 1 to 3, depending on its severity, and the scores are added up to give a total score. The total score is then used to grade the severity of the disease as A, B, or C.

The MELD system uses a formula that takes into account a patient’s bilirubin, creatinine, and international normalized ratio (INR) to predict their survival. The formula calculates a score that ranges from 6 to 40, with higher scores indicating a higher risk of mortality. The MELD score is particularly useful for patients who are on a liver transplant waiting list, as it helps to prioritize patients based on their risk of mortality. Overall, both the Child-Pugh classification and the MELD system are important tools for assessing the severity of liver cirrhosis and determining the best course of treatment for patients.

For a patient experiencing mild-to-moderate symptoms of distal ulcerative colitis, the recommended first-line treatment is topical (rectal) aminosalicylates, such as mesalazine suppositories. This is particularly effective for patients with left-sided disease, such as proctitis or proctosigmoiditis. While budesonide foam enema is sometimes used as an additional treatment for mild-to-moderate disease, it is generally less effective at inducing remission. Oral azathioprine is not recommended for inducing remission, but may be used to maintain remission in patients who have had multiple inflammatory exacerbations or if remission is not maintained by aminosalicylates alone. Oral mesalazine is less effective than topical mesalazine for mild or moderate proctitis, but may be offered as an additional treatment if symptoms persist after 4 weeks of topical mesalazine. For patients with pancolitis or extensive disease, oral mesalazine may be offered as a first-line treatment.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools per day, the amount of blood, and the presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Severe cases should be treated in a hospital setting with intravenous steroids or ciclosporin.

To maintain remission, patients with proctitis and proctosigmoiditis may use topical aminosalicylate alone or in combination with an oral aminosalicylate. Those with left-sided and extensive ulcerative colitis may require a low maintenance dose of an oral aminosalicylate. Patients who have experienced severe relapses or multiple exacerbations may benefit from oral azathioprine or mercaptopurine. Methotrexate is not recommended for UC management, but probiotics may help prevent relapse in mild to moderate cases.

In summary, the management of ulcerative colitis involves a combination of inducing and maintaining remission. Treatment options vary depending on the severity and location of the condition, with mild-to-moderate cases typically treated with topical aminosalicylate and severe cases requiring hospitalization and intravenous medication. Maintaining remission may involve using a combination of oral and topical medications or a low maintenance dose of an oral aminosalicylate. While methotrexate is not recommended, probiotics may be helpful in preventing relapse in mild to moderate cases.

NICE advises against the use of lactulose for the treatment of IBS.

Managing irritable bowel syndrome (IBS) can be challenging and varies from patient to patient. The National Institute for Health and Care Excellence (NICE) updated its guidelines in 2015 to provide recommendations for the management of IBS. The first-line pharmacological treatment depends on the predominant symptom, with antispasmodic agents recommended for pain, laxatives (excluding lactulose) for constipation, and loperamide for diarrhea. If conventional laxatives are not effective for constipation, linaclotide may be considered. Low-dose tricyclic antidepressants are the second-line pharmacological treatment of choice. For patients who do not respond to pharmacological treatments, psychological interventions such as cognitive behavioral therapy, hypnotherapy, or psychological therapy may be considered. Complementary and alternative medicines such as acupuncture or reflexology are not recommended. General dietary advice includes having regular meals, drinking at least 8 cups of fluid per day, limiting tea and coffee to 3 cups per day, reducing alcohol and fizzy drink intake, limiting high-fiber and resistant starch foods, and increasing intake of oats and linseeds for wind and bloating.

Understanding the Mechanism of Action of Parkinson’s Drugs

Parkinson’s disease is a complex condition that requires specialized management. The first-line treatment for motor symptoms that affect a patient’s quality of life is levodopa, while dopamine agonists, levodopa, or monoamine oxidase B (MAO-B) inhibitors are recommended for those whose motor symptoms do not affect their quality of life. However, all drugs used to treat Parkinson’s can cause a wide variety of side effects, and it is important to be aware of these when making treatment decisions.

Levodopa is nearly always combined with a decarboxylase inhibitor to prevent the peripheral metabolism of levodopa to dopamine outside of the brain and reduce side effects. Dopamine receptor agonists, such as bromocriptine, ropinirole, cabergoline, and apomorphine, are more likely than levodopa to cause hallucinations in older patients. MAO-B inhibitors, such as selegiline, inhibit the breakdown of dopamine secreted by the dopaminergic neurons. Amantadine’s mechanism is not fully understood, but it probably increases dopamine release and inhibits its uptake at dopaminergic synapses. COMT inhibitors, such as entacapone and tolcapone, are used in conjunction with levodopa in patients with established PD. Antimuscarinics, such as procyclidine, benzotropine, and trihexyphenidyl (benzhexol), block cholinergic receptors and are now used more to treat drug-induced parkinsonism rather than idiopathic Parkinson’s disease.

It is important to note that all drugs used to treat Parkinson’s can cause adverse effects, and clinicians must be aware of these when making treatment decisions. Patients should also be warned about the potential for dopamine receptor agonists to cause impulse control disorders and excessive daytime somnolence. Understanding the mechanism of action of Parkinson’s drugs is crucial in managing the condition effectively.

Understanding Primary Biliary Cholangitis: Diagnostic Tests and Markers

Primary biliary cholangitis is an autoimmune disease that affects the biliary system, causing intrahepatic cholestasis and leading to cell damage, fibrosis, and cirrhosis. While there is no single definitive test for this condition, several markers can help diagnose and monitor it.

Antimitochondrial antibodies are present in 90-95% of individuals with primary biliary cholangitis, but are only found in 0.5% of normal controls. Anti-smooth muscle antibodies are also nonspecific, as they can be positive in connective tissue disease and chronic infections. Similarly, around 35% of patients with primary biliary cholangitis have positive antinuclear antibodies, but this is not specific to the condition.

Elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are common in primary biliary cholangitis, but significant elevations of alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) are usually more prominent. Additionally, a polyclonal increase in IgM (sometimes associated with elevated IgG) is typical but not specific to this condition.

Overall, a combination of these diagnostic tests and markers can help identify and monitor primary biliary cholangitis.

The patient’s symptoms suggest a diagnosis of achalasia, which is characterized by the failure of the lower oesophageal sphincter to relax, leading to a functional stricture. This can cause substernal cramps, regurgitation, and pulmonary aspiration due to the retention of food and saliva in the oesophagus, resulting in a nocturnal cough. Diagnosis is made using a barium swallow, and treatment involves endoscopic balloon dilation or cardiomyotomy. Barrett’s oesophagus, motor neurone disease, oesophageal carcinoma, and pharyngeal pouch are less likely diagnoses based on the patient’s age, symptoms, and medical history.

When a patient experiences a mild-moderate flare of ulcerative colitis that extends beyond the left-sided colon, it is recommended to add oral aminosalicylates to rectal aminosalicylates. This is because enemas can only reach a certain point and the addition of an oral medication ensures proper treatment. In this case, the patient’s colonoscopy showed extensive disease, making the use of an oral aminosalicylate necessary. Therefore, this is the correct option and using rectal mesalazine alone is not sufficient.

Using oral steroids like prednisolone and dexamethasone as a first-line treatment is not recommended.

Metronidazole is used to treat bacterial infections, but there is no indication of such an infection in this case.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools per day, the amount of blood, and the presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Severe cases should be treated in a hospital setting with intravenous steroids or ciclosporin.

To maintain remission, patients with proctitis and proctosigmoiditis may use topical aminosalicylate alone or in combination with an oral aminosalicylate. Those with left-sided and extensive ulcerative colitis may require a low maintenance dose of an oral aminosalicylate. Patients who have experienced severe relapses or multiple exacerbations may benefit from oral azathioprine or mercaptopurine. Methotrexate is not recommended for UC management, but probiotics may help prevent relapse in mild to moderate cases.

In summary, the management of ulcerative colitis involves a combination of inducing and maintaining remission. Treatment options vary depending on the severity and location of the condition, with mild-to-moderate cases typically treated with topical aminosalicylate and severe cases requiring hospitalization and intravenous medication. Maintaining remission may involve using a combination of oral and topical medications or a low maintenance dose of an oral aminosalicylate. While methotrexate is not recommended, probiotics may be helpful in preventing relapse in mild to moderate cases.

NICE Guidelines for Upper GI Endoscopy and GORD Treatment

According to the latest NICE guidance NG12 (updated in October 2015), patients with certain symptoms should be referred for upper gastrointestinal (GI) endoscopy. Urgent direct access upper GI endoscopy should be offered to those with dysphagia or aged 55 and over with weight loss and upper abdominal pain, reflux, or dyspepsia. Non-urgent direct access upper GI endoscopy should be considered for those with haematemesis, treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, raised platelet count with certain symptoms, or nausea/vomiting with certain symptoms.

For mild gastro-oesophageal reflux disease (GORD) symptoms occurring less than once a week, antacids can be used as needed. For more frequent symptoms, a proton pump inhibitor (PPI) is recommended. Initial treatment is a high dose PPI for four weeks, taken once daily 30-60 minutes before the first meal of the day. If symptoms persist after one month, offer another month at full dose. Doubling the dose of PPI can be considered for severe symptoms. If there is no response to PPI treatment, reconsider the diagnosis and consider specialist referral. A H2 receptor antagonist can be added to a PPI for patients with a partial response to PPI treatment.

Management of Diverticulitis in Primary Care

Diverticulitis is a common condition that can be managed in primary care, provided there are no complications. If the patient is not dehydrated, experiencing severe bleeding, or showing signs of perforation, abscess or fistula formation, or significant comorbidity, they can be treated at home.

The first step in treatment is to prescribe broad-spectrum antibiotics that cover anaerobes and Gram-negative rods. Co-amoxiclav or a combination of ciprofloxacin and metronidazole (if allergic to penicillin) are good options. The course of antibiotics should last for at least 7 days.

If the patient’s symptoms worsen or persist beyond 48 hours, hospital admission may be necessary. However, with proper management and monitoring, most cases of diverticulitis can be successfully treated in primary care.

Understanding Hepatitis B and Related Tests

Hepatitis B is a viral infection that affects the liver. There are different stages of the disease, and various tests can help diagnose and monitor it.

Active Hepatitis B Infection:
The presence of HBeAg in the blood indicates ongoing viral replication and is associated with large quantities of HBV DNA. Patients who have not developed anti-HBeAb are highly infectious and at greater risk of progressing to chronic liver disease.

Chronic Hepatitis B in an Inactive State:
Patients in the inactive carrier state have cleared HBeAg and have low levels of HBV DNA. However, they will still test positive for surface antigen.

Cirrhosis of the Liver:
Hepatitis B patients are at risk of developing cirrhosis, which is diagnosed clinically, on ultrasound, and with liver biopsy.

Hepatitis E:
Hepatitis E is a different viral infection spread via the faecal-oral route and is tested for with hepatitis E antibodies.

Previous Hepatitis B Vaccination:
Patients who have been vaccinated against hepatitis B will show antibodies to the surface antibody (anti-HBsAb) only. This doesn’t account for deranged LFTs.

Understanding Hepatitis B and Related Tests

To accurately test for coeliac disease, patients must consume gluten for a minimum of 6 weeks before undergoing the first-line test, which involves measuring serum total immunoglobulin A (IgA) and IgA tissue transglutaminase (tTG) levels. Failure to consume gluten prior to the test may result in a false negative result. If a patient refuses to consume gluten, they should be referred to a Gastroenterologist, but it should be noted that even an endoscopy and biopsy may yield a negative result if gluten has been excluded from the diet.

Investigating Coeliac Disease

Coeliac disease is a condition caused by sensitivity to gluten, which leads to villous atrophy and malabsorption. It is often associated with other conditions such as dermatitis herpetiformis and autoimmune disorders. Diagnosis is made through a combination of serology and endoscopic intestinal biopsy, with villous atrophy and immunology typically reversing on a gluten-free diet.

To investigate coeliac disease, NICE guidelines recommend using tissue transglutaminase (TTG) antibodies (IgA) as the first-choice serology test, along with endomyseal antibody (IgA) and testing for selective IgA deficiency. Anti-gliadin antibody (IgA or IgG) tests are not recommended. The ‘gold standard’ for diagnosis is an endoscopic intestinal biopsy, which should be performed in all suspected cases to confirm or exclude the diagnosis. Findings supportive of coeliac disease include villous atrophy, crypt hyperplasia, increase in intraepithelial lymphocytes, and lamina propria infiltration with lymphocytes. Rectal gluten challenge is a less commonly used method.

In summary, investigating coeliac disease involves a combination of serology and endoscopic intestinal biopsy, with NICE guidelines recommending specific tests and the ‘gold standard’ being an intestinal biopsy. Findings supportive of coeliac disease include villous atrophy, crypt hyperplasia, and lymphocyte infiltration.

Non-alcoholic fatty liver disease may be considered as a potential cause of abnormal liver function tests in patients with type 2 diabetes mellitus.

Non-Alcoholic Fatty Liver Disease: Causes, Features, and Management

Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disease in developed countries, primarily caused by obesity. It is a spectrum of disease that ranges from simple steatosis (fat in the liver) to steatohepatitis (fat with inflammation) and may progress to fibrosis and liver cirrhosis. NAFLD is believed to be the hepatic manifestation of the metabolic syndrome, with insulin resistance as the key mechanism leading to steatosis. Non-alcoholic steatohepatitis (NASH) is a term used to describe liver changes similar to those seen in alcoholic hepatitis but without a history of alcohol abuse.

NAFLD is usually asymptomatic, but patients may present with hepatomegaly, increased echogenicity on ultrasound, and elevated ALT levels. The enhanced liver fibrosis (ELF) blood test is recommended by NICE to check for advanced fibrosis in patients with incidental findings of NAFLD. If the ELF blood test is not available, non-invasive tests such as the FIB4 score or NAFLD fibrosis score may be used in combination with a FibroScan to assess the severity of fibrosis. Patients with advanced fibrosis should be referred to a liver specialist for further evaluation, which may include a liver biopsy to stage the disease more accurately.

The mainstay of treatment for NAFLD is lifestyle changes, particularly weight loss, and monitoring. There is ongoing research into the role of gastric banding and insulin-sensitizing drugs such as metformin and pioglitazone in the management of NAFLD. While there is no evidence to support screening for NAFLD in adults, it is essential to identify and manage incidental findings of NAFLD to prevent disease progression and complications.

Understanding Crohn’s Disease: Symptoms, Diagnosis, and Differential Diagnosis

Crohn’s disease is a chronic inflammatory condition that can affect any part of the gastrointestinal tract. The most commonly affected sites are the ileocecal region and the colon. Patients with Crohn’s disease experience relapses and remissions, with symptoms including low-grade fever, prolonged diarrhea, right lower quadrant or periumbilical pain, weight loss, and fatigue. Perianal disease may also occur, with symptoms such as perirectal pain, malodorous discharge, and fistula formation. Extra-intestinal manifestations may include arthritis, erythema nodosum, and primary sclerosing cholangitis.

To establish a diagnosis of Crohn’s disease, ileocolonoscopy and biopsies from affected areas are first-line procedures. A cobblestone-like appearance is often seen, representing areas of ulceration separated by narrow areas of healthy tissue. Barium follow-through examination is useful for looking for inflammation and narrowing of the small bowel.

Differential diagnosis for Crohn’s disease include coeliac disease, small bowel lymphoma, tropical sprue, and ulcerative colitis. Coeliac disease presents as a malabsorption syndrome with weight loss and steatorrhoea, while small bowel lymphoma is rare and presents with nonspecific symptoms such as abdominal pain and weight loss. Tropical sprue is a post-infectious malabsorption syndrome that occurs in tropical areas, and ulcerative colitis may be clinically indistinguishable from colonic Crohn’s disease but lacks the small bowel involvement and skip lesions seen in Crohn’s disease.

Abdominal Migraine: Recurrent Episodes of Midline Abdominal Pain in Children

Abdominal migraine is a disorder that mainly affects children and is characterized by recurrent episodes of midline abdominal pain. The pain can last from 1-72 hours and is of moderate to severe intensity. During the attacks, patients may experience anorexia, nausea, and vomiting. Marked pallor is commonly noted, and some patients may appear flushed. The pain is severe enough to interfere with normal daily activities, and many children describe their mood during the attack as one of intense misery. However, patients are completely symptom-free between attacks.

Abdominal migraine is an idiopathic disorder, meaning that the cause is unknown. It is unlikely to be school avoidance as the symptoms are episodic and can occur outside of school times.

If initial treatment for dyspepsia with either a PPI or ‘test and treat’ approach fails, the alternative strategy should be tried next. In Mark’s case, he has completed 1 month of a full-dose PPI and should now be tested for H. pylori infection. Referral for routine upper gastrointestinal endoscopy is not necessary at this stage.

Management of Dyspepsia and Referral Criteria for Suspected Cancer

Dyspepsia is a common condition that can be managed through a stepwise approach. The first step is to review medications that may be causing dyspepsia and provide lifestyle advice. If symptoms persist, a full-dose proton pump inhibitor or a ‘test and treat’ approach for H. pylori can be tried for one month. If symptoms still persist, the alternative approach should be attempted.

For patients who meet referral criteria for suspected cancer, urgent referral for an endoscopy within two weeks is necessary. This includes patients with dysphagia, an upper abdominal mass consistent with stomach cancer, and patients aged 55 years or older with weight loss and upper abdominal pain, reflux, or dyspepsia. Non-urgent referral is recommended for patients with haematemesis and patients aged 55 years or older with treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, or raised platelet count with symptoms such as nausea, vomiting, weight loss, reflux, dyspepsia, or upper abdominal pain.

Testing for H. pylori infection can be done through a carbon-13 urea breath test, stool antigen test, or laboratory-based serology. If symptoms have resolved following a ‘test and treat’ approach, there is no need to check for H. pylori eradication. However, if repeat testing is required, a carbon-13 urea breath test should be used.

A non-urgent referral to GI is necessary for patients who have both raised platelet count and nausea due to dyspepsia. In this case, the patient, who is 58 years old, meets the criteria for such referral.

While ondansetron is effective for chemically mediated nausea, metoclopramide or domperidone may be more appropriate for patients with reduced gastric motility.

PPI trial is typically used as a second line management for dyspepsia patients who do not require endoscopy referral.

Reassurance should not be given to patients who meet the criteria for non-urgent endoscopy referral, such as this man with dyspepsia symptoms and abnormal blood results.

Urgent endoscopy referral is not necessary for patients who only present with nausea.

Management of Dyspepsia and Referral Criteria for Suspected Cancer

Dyspepsia is a common condition that can be managed through a stepwise approach. The first step is to review medications that may be causing dyspepsia and provide lifestyle advice. If symptoms persist, a full-dose proton pump inhibitor or a ‘test and treat’ approach for H. pylori can be tried for one month. If symptoms still persist, the alternative approach should be attempted.

For patients who meet referral criteria for suspected cancer, urgent referral for an endoscopy within two weeks is necessary. This includes patients with dysphagia, an upper abdominal mass consistent with stomach cancer, and patients aged 55 years or older with weight loss and upper abdominal pain, reflux, or dyspepsia. Non-urgent referral is recommended for patients with haematemesis and patients aged 55 years or older with treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, or raised platelet count with symptoms such as nausea, vomiting, weight loss, reflux, dyspepsia, or upper abdominal pain.

Testing for H. pylori infection can be done through a carbon-13 urea breath test, stool antigen test, or laboratory-based serology. If symptoms have resolved following a ‘test and treat’ approach, there is no need to check for H. pylori eradication. However, if repeat testing is required, a carbon-13 urea breath test should be used.

Identifying Symptoms of Colorectal Cancer: Referral Recommendations and Differential Diagnosis

Colorectal cancer is a serious condition that requires prompt diagnosis and treatment. According to the National Institute for Health and Care Excellence (NICE), patients over 50 years old with unexplained rectal bleeding or over 60 years old with a change in bowel habit should be referred for an appointment within 2 weeks for suspected colorectal cancer. However, other conditions can also cause similar symptoms, and differential diagnosis is important to ensure appropriate management.

Rectal Bleeding in a Multiparous Woman

Rectal bleeding is a common symptom that can be caused by various conditions, including haemorrhoids. In a 40-year-old multiparous woman, routine referral would be appropriate if piles could not be identified.

Change in Bowel Habit in a 60-Year-Old Man

A change in bowel habit in a 60-year-old man is more likely to be caused by an acute infection, such as enterohaemorrhagic E. coli or Shigella. Investigations should be directed to finding the cause.

Constipation in an 80-Year-Old Woman

Constipation is a common symptom in the elderly, and dietary factors may play a role. In an 80-year-old woman with intermittent constipation and no teeth, the symptom is likely to be longstanding and not indicative of colorectal cancer.

Anal Fissure in a 70-Year-Old Man

Anal fissure is a possible cause of rectal bleeding in a 70-year-old man. Further investigation is needed to confirm the diagnosis and rule out other conditions.

Identifying Symptoms of Colorectal Cancer: Referral Recommendations and Differential Diagnosis

Retesting for Helicobacter pylori after Eradication Therapy

The NICE guidelines on Dyspepsia (CG184) provide recommendations for retesting patients who have received eradication therapy for Helicobacter pylori. The first-line tests for detecting H. pylori are the stool antigen test and the urea breath test, while serological testing can be used if locally validated. However, serology is not appropriate for retesting as it remains positive due to past exposure. Saliva assays are inconsistent in accuracy, and gastric biopsy is invasive and costly.

If a patient tests positive for H. pylori and receives eradication therapy, retesting may be necessary. Currently, there is insufficient evidence to recommend stool antigen testing as a test of eradication. Therefore, NICE recommends retesting via the urea breath test.

Understanding Diverticulosis and Diverticulitis: Symptoms and Management

Diverticulosis is a condition where small pouches called diverticula form in the lining of the colon. About 75% of people with diverticula have no symptoms. However, those with uncomplicated diverticulosis may experience lower abdominal pain, bloating, constipation, or rectal bleeding. These symptoms may be exacerbated by eating and relieved by defecation or flatus. Left lower quadrant tenderness and fullness may also be present, which can be mistaken for irritable bowel syndrome.

On the other hand, diverticulitis is a more serious condition where the diverticula become inflamed or infected. Patients with diverticulitis may experience intermittent or constant left lower quadrant pain, accompanied by a change in bowel habits. Pyrexia and tachycardia are common, and examination usually reveals localised tenderness and sometimes a palpable mass. Mild cases of diverticulitis can be managed at home with paracetamol, clear fluids, and oral antibiotics. However, one third of patients may develop further complications such as perforation, abscess, fistula, or stricture/obstruction.

It is important to differentiate diverticulitis from other conditions such as colonic cancer, Crohn’s disease, and ulcerative colitis. Colonic cancer may present with weight loss and a more definite change in bowel habit, while Crohn’s disease and ulcerative colitis usually present with diarrhoea at a younger age than diverticulitis. Barium enema or colonoscopy may be needed to confirm the diagnosis.

In summary, understanding the symptoms and management of diverticulosis and diverticulitis is crucial for early detection and treatment. Patients with mild diverticulitis can be managed at home, but those with severe symptoms or complications require hospitalisation and possibly surgery. Regular screening and follow-up are recommended for those with diverticulosis to prevent complications.

Causes of Jaundice: Identifying the Culprit in a Clinical Case

In this clinical case, a patient presents with jaundice and abnormal liver function tests. The following potential causes are considered:

Flucloxacillin: The patient’s presentation is consistent with cholestatic jaundice, which can be caused by flucloxacillin. Other drugs that can cause a similar picture include chlorpromazine, azathioprine, captopril, ciclosporin, penicillamine, erythromycin, and the combined oral contraceptive.

Ethanol: Although the patient reports occasional alcohol use, ethanol is an unlikely cause of cholestatic jaundice. Ethanol more commonly causes a hepatitic picture with elevated transaminase levels.

Gallstones: Cholecystitis typically doesn’t cause jaundice. If gallstones were the cause, right upper quadrant pain and tenderness would be expected.

Paracetamol: The patient is taking paracetamol, but there is no information about excessive use. Paracetamol overdose typically causes a hepatitic picture rather than cholestatic jaundice.

Phenytoin: Phenytoin typically causes a hepatitic picture with larger elevations in transaminase levels and a smaller rise in ALP levels.

In conclusion, flucloxacillin is the most likely cause of this patient’s cholestatic jaundice.

Serological testing for coeliac disease is used to determine if further investigation is necessary. The preferred first choice test is IgA transglutaminase, with IgA endomysial antibodies used if the result is equivocal. False negative results can occur in those with IgA deficiency, so this should be ruled out. HLA testing may be considered in specific situations but is not necessary for initial testing. If there is significant clinical suspicion of coeliac disease despite negative serological testing, referral to a specialist should still be offered. Accuracy of testing depends on following a gluten-containing diet for at least six weeks prior to testing. A clinical response to a gluten-free diet is not diagnostic of coeliac disease.

Orlistat Prescription Guidelines

Orlistat is a medication that inhibits pancreatic lipase and is prescribed to patients with a BMI of 30 kg/m2 or more (or 28 kg/m2 with an associated risk factor). Patients are expected to lose 5% of their initial body weight at 3 months for the prescription to be continued. However, for patients with diabetes, a 3% loss of body weight at 3 months is recommended.

Beyond the initial weight loss at 3 months, there is no restriction on how long orlistat should be prescribed. The decision to continue treatment should be made on an individual basis, taking into account the benefits, risks, and cost of treatment. Regular reviews should be undertaken to assess the benefits, risks, and costs of treatment. According to NICE, For people who have lost the recommended amount of weight, there is no restriction on how long orlistat may be prescribed. This should be reviewed at regular intervals.

In summary, orlistat is a medication that can be prescribed for an extended period of time, but the decision to continue treatment should be made on an individual basis, taking into account the benefits, risks, and cost of treatment. Regular reviews should be conducted to ensure that the medication is still appropriate for the patient.

Upon diagnosis, approximately 66% of individuals with inflammatory bowel disease exhibit anaemia. Crohn’s disease is typically diagnosed at a median age of 30 years. The global incidence and prevalence of Crohn’s disease are on the rise.

Osteoporosis is a condition that is more prevalent in women and increases with age. However, there are many other risk factors and secondary causes of osteoporosis. Some of the most significant risk factors include a history of glucocorticoid use, rheumatoid arthritis, alcohol excess, parental hip fracture history, low body mass index, and current smoking. Other risk factors include a sedentary lifestyle, premature menopause, certain ethnicities, endocrine disorders, gastrointestinal disorders, chronic kidney disease, and certain genetic disorders. Additionally, certain medications such as SSRIs, antiepileptics, and proton pump inhibitors may worsen osteoporosis.

If a patient is diagnosed with osteoporosis or has a fragility fracture, further investigations may be necessary to identify the cause of osteoporosis and assess the risk of subsequent fractures. Recommended investigations include a history and physical examination, blood tests such as a full blood count, urea and electrolytes, liver function tests, bone profile, CRP, and thyroid function tests. Other procedures may include bone densitometry, lateral radiographs, protein immunoelectrophoresis, and urinary Bence-Jones proteins. Additionally, markers of bone turnover and urinary calcium excretion may be assessed. By identifying the cause of osteoporosis and contributory factors, healthcare providers can select the most appropriate form of treatment.

Differential Diagnosis for a Patient with Ulcerative Colitis and Deranged Liver Function

Ulcerative colitis (UC) is associated with various conditions, including primary sclerosing cholangitis (PSC), which confers a high risk for cholangiocarcinoma. Therefore, a patient with UC and deranged liver function is likely to have cancer, specifically cholangiocarcinoma. Gallstones, chronic pancreatitis, and small bowel lymphoma are less likely diagnoses due to their lack of association with UC and/or absence of relevant symptoms. Primary biliary cholangitis is a possibility, but its incidence is not increased in patients with UC. Overall, cholangiocarcinoma should be considered as a potential diagnosis in a patient with UC and deranged liver function.

NICE recommends the use of faecal calprotectin in primary care to distinguish between IBS and IBD. This protein is released in the bowel during inflammation and can be detected in a stool sample. Its use can reduce the need for invasive diagnostic testing and referral of patients with typical IBS symptoms. However, a positive result doesn’t confirm IBD and patients should be referred to secondary care for further investigation.

NICE has also provided guidance on the diagnostic criteria for IBS and the necessary investigations. They suggest conducting FBC, ESR, CRP, and coeliac screen (TTG). However, they advise against performing ultrasound, sigmoidoscopy or colonoscopy, barium study, thyroid function test, stool microscopy and culture, and faecal occult blood and hydrogen breath test.

Understanding Diarrhoea: Causes and Characteristics

Diarrhoea is defined as having more than three loose or watery stools per day. It can be classified as acute if it lasts for less than 14 days and chronic if it persists for more than 14 days. Gastroenteritis, diverticulitis, and antibiotic therapy are common causes of acute diarrhoea. On the other hand, irritable bowel syndrome, ulcerative colitis, Crohn’s disease, colorectal cancer, and coeliac disease are some of the conditions that can cause chronic diarrhoea.

Symptoms of gastroenteritis may include abdominal pain, nausea, and vomiting. Diverticulitis is characterized by left lower quadrant pain, diarrhoea, and fever. Antibiotic therapy, especially with broad-spectrum antibiotics, can also cause diarrhoea, including Clostridioides difficile infection. Chronic diarrhoea may be caused by irritable bowel syndrome, which is characterized by abdominal pain, bloating, and changes in bowel habits. Ulcerative colitis may cause bloody diarrhoea, crampy abdominal pain, and weight loss. Crohn’s disease may cause crampy abdominal pain, diarrhoea, and malabsorption. Colorectal cancer may cause diarrhoea, rectal bleeding, anaemia, and weight loss. Coeliac disease may cause diarrhoea, abdominal distension, lethargy, and weight loss.

Other conditions associated with diarrhoea include thyrotoxicosis, laxative abuse, appendicitis, and radiation enteritis. It is important to seek medical attention if diarrhoea persists for more than a few days or is accompanied by other symptoms such as fever, severe abdominal pain, or blood in the stool.

Possible Causes of Jaundice: A Differential Diagnosis

Jaundice is a common clinical manifestation of various diseases. In this case, the patient presents with jaundice, and the differential diagnosis includes several inherited disorders of bilirubin metabolism, chronic haemolytic disorders, and infectious diseases.

Gilbert Syndrome: This is a relatively mild inherited disorder caused by a deficiency of glucuronosyl transferase, resulting in an accumulation of unconjugated bilirubin. The jaundice usually subsides in a few days and may be more obvious during an intercurrent illness.

Dubin–Johnson Syndrome: This is another inherited disorder of bilirubin metabolism, but in this case, there is a defect in the secretion of bilirubin from the liver. The bilirubin that accumulates in the plasma is conjugated, water-soluble, and excreted in the urine. Onset of jaundice may commonly first occur during puberty or early adulthood and can be precipitated by alcohol, infection, pregnancy, or contraceptive pill use.

Hereditary Spherocytosis: This is a chronic haemolytic disorder due to a defect in the red cell membrane, most frequently in spectrin, a structural protein. It can present with a wide range of severity, from jaundice at birth to asymptomatic anaemia or jaundice in adults.

Infectious Mononucleosis: This viral infection can cause hepatitis and jaundice, but elevated transaminase activity would be expected.

Rotor Syndrome: This is a possible differential diagnosis, but this condition would cause a mixed hyperbilirubinaemia. Therefore, Gilbert’s disease is the more likely diagnosis in this scenario.

In conclusion, the differential diagnosis of jaundice includes several inherited disorders of bilirubin metabolism, chronic haemolytic disorders, and infectious diseases. A thorough evaluation of the patient’s medical history, physical examination, and laboratory tests is necessary to establish the correct diagnosis and provide appropriate treatment.

NICE Guidelines for Referral of Suspected Colorectal Cancer

According to the National Institute for Health and Care Excellence (NICE) guidelines, individuals under the age of 50 who experience a change in bowel habit to looser and/or more frequent stools, along with rectal bleeding, should be urgently referred for suspected colorectal cancer.

In addition, NICE recommends considering a suspected cancer pathway referral for adults under 50 with rectal bleeding and unexplained symptoms such as abdominal pain, weight loss, and iron-deficiency anemia. These referrals should result in an appointment within two weeks to ensure prompt diagnosis and treatment.

It is important to follow these guidelines to ensure early detection and treatment of colorectal cancer, which can significantly improve outcomes for patients.